Zhejiang Starry PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 2/6
Zhejiang Starry PharmaceuticalLtd has a total shareholder equity of CN¥2.7B and total debt of CN¥2.6B, which brings its debt-to-equity ratio to 96.5%. Its total assets and total liabilities are CN¥5.9B and CN¥3.2B respectively. Zhejiang Starry PharmaceuticalLtd's EBIT is CN¥127.1M making its interest coverage ratio 1.5. It has cash and short-term investments of CN¥686.2M.
Key information
96.5%
Debt to equity ratio
CN¥2.58b
Debt
| Interest coverage ratio | 1.5x |
| Cash | CN¥686.23m |
| Equity | CN¥2.67b |
| Total liabilities | CN¥3.20b |
| Total assets | CN¥5.88b |
Recent financial health updates
Recent updates
There's No Escaping Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Muted Revenues
Sep 30
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality
May 06Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost
Mar 12Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?
Feb 28Financial Position Analysis
Short Term Liabilities: 603520's short term assets (CN¥2.3B) do not cover its short term liabilities (CN¥2.6B).
Long Term Liabilities: 603520's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥616.2M).
Debt to Equity History and Analysis
Debt Level: 603520's net debt to equity ratio (70.9%) is considered high.
Reducing Debt: 603520's debt to equity ratio has reduced from 199.7% to 96.5% over the past 5 years.
Debt Coverage: 603520's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 603520's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 21:05 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Starry Pharmaceutical Co.,Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yue Gao | Changjiang Securities Co. LTD. |
| Xu Qing Liu | Chasing Securities |
| Feifei Xu | China Merchants Securities Co. Ltd. |